Clinical Trial Update: A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer [Phase 3]

View source ↗

Summary

Clinical trial update for KN026 in combination with HB1801 as adjuvant therapy for resectable HER2-positive breast cancer, currently recruiting in Phase III.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HB1801
• KN026

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Resectable HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING